Krishna Saxena

Nov 25, 2024 | nature.com | Martin P. Schwalm |Johannes Dopfer |Adarsh Kumar |Francesco Greco |Nicolas Bauer |Frank Lohr | +18 more

AbstractRecent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community.

Apr 18, 2024 | nature.com | Martin P. Schwalm |Krishna Saxena |Susanne Müller

AbstractThe rational development of small-molecule degraders (e.g., proteolysis targeting chimeras) remains a challenge as the rate-limiting steps that determine degrader efficiency are largely unknown. Standard methods in the field of targeted protein degradation mostly rely on classical, low-throughput endpoint assays such as western blots or quantitative proteomics.